HUGE logo

FSD Pharma (HUGE) Stock

Profile

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

Canada

IPO:

08 June 2018

Indexes:

Not included

Website:

http://www.fsdpharma.com

Description:

HUGE (FSD Pharma) is a biotechnology company focused on developing innovative cannabis-based products. They aim to improve health and wellness through research and development of pharmaceuticals derived from cannabis. Their mission is to create effective treatments for various medical conditions while ensuring safety and quality.

Key Details

Price

-

Market Cap

-

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

-

Annual EPS

-$0.46(+24.59% YoY)

PE Ratio

-

Annual ROE

-135.25%

Annual Debt To Equity

0.03

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 31, 2022
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Aug 15, 2024

Analyst ratings

Recent major analysts updates

No data about analysts updates

Screeners with HUGE included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$9080.40
HUGE price is currently at an all-time high

Price Analysts Target

$2.60
HUGE price is currently equal to the consensus analysts' forecast

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Net Income 3-Year Change

+43.7%
HUGE annual net profit is up +43.7% over the past 3 years

Annual EPS 3-Year Change

+82.58%
HUGE annual earnings per share is up +82.58% over the past 3 years

Annual EPS Estimate

-$0.22
HUGE annual earnings per share is currently +109.09% higher than the consensus analysts' forecast

Annual Operating Profit

-$19.57 M
HUGE annual operaing income is -$19.57 million

Annual Operating Profit 3-Year Change

+36.05%
HUGE annual operaing income is up +36.05% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

-135.25%
HUGE annual return on equity is -135.25%

Annual ROA

-102.45%
HUGE annual return on assets is -102.45%

Annual EBIT

-$18.23 M
HUGE annual earnings before interest & taxes is -$18.23 million

Annual EBITDA

-$15.72 M
HUGE annual earnings before interest, taxes, depreciation & amortization is -$15.72 million

Annual Interest Coverage Ratio

-60.77 K
HUGE annual interest coverage ratio is -60.77 thousand

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Current Ratio

2.43
HUGE annual current ratio is 2.43

Annual Total Assets

$17.47 M
HUGE annual total assets is $17.47 million

Annual Current Assets

$11.09 M
HUGE annual total current assets is $11.09 million

Annual Total Liabilities

$4.57 M
HUGE annual total liabilities is $4.57 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+43.4%
HUGE annual cash flow from operations is up +43.4% over the past 3 years

Annual CFI 3-Year Change

-104.14%
HUGE annual cash flow from investing activities is down -104.14% over the past 3 years

Annual CFF 3-Year Change

-112.93%
HUGE annual cash flow from financing activities is down -112.93% over the past 3 years

Annual FCF

-$10.83 M
HUGE annual free cash flow is -$10.83 million

Annual FCF 3-Year Change

+43.4%
HUGE annual free cash flow is up +43.4% over the past 3 years

Institutional Ownership

Similar stocks

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
HUGE
Accesswire15 August 2023

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system.

FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
HUGE
Business Wire08 May 2023

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings wit.

FAQ

  • What is the primary business of FSD Pharma?
  • What is the ticker symbol for FSD Pharma?
  • Does FSD Pharma pay dividends?
  • What sector is FSD Pharma in?
  • What industry is FSD Pharma in?
  • What country is FSD Pharma based in?
  • When did FSD Pharma go public?
  • Is FSD Pharma in the S&P 500?
  • Is FSD Pharma in the NASDAQ 100?
  • Is FSD Pharma in the Dow Jones?
  • When was FSD Pharma's last earnings report?
  • When does FSD Pharma report earnings?
  • Should I buy FSD Pharma stock now?

What is the primary business of FSD Pharma?

HUGE (FSD Pharma) is a biotechnology company focused on developing innovative cannabis-based products. They aim to improve health and wellness through research and development of pharmaceuticals derived from cannabis. Their mission is to create effective treatments for various medical conditions while ensuring safety and quality.

What is the ticker symbol for FSD Pharma?

The ticker symbol for FSD Pharma is NASDAQ:HUGE

Does FSD Pharma pay dividends?

No, FSD Pharma does not pay dividends

What sector is FSD Pharma in?

FSD Pharma is in the Healthcare sector

What industry is FSD Pharma in?

FSD Pharma is in the Drug Manufacturers - Specialty & Generic industry

What country is FSD Pharma based in?

FSD Pharma is headquartered in Canada

When did FSD Pharma go public?

FSD Pharma's initial public offering (IPO) was on 08 June 2018

Is FSD Pharma in the S&P 500?

No, FSD Pharma is not included in the S&P 500 index

Is FSD Pharma in the NASDAQ 100?

No, FSD Pharma is not included in the NASDAQ 100 index

Is FSD Pharma in the Dow Jones?

No, FSD Pharma is not included in the Dow Jones index

When was FSD Pharma's last earnings report?

FSD Pharma's most recent earnings report was on 14 November 2024

When does FSD Pharma report earnings?

The date for FSD Pharma's next earnings report has not been announced yet

Should I buy FSD Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions